Study: Intracranial bleeding risk lower in rivaroxaban users

02/3/2012 | Family Practice News

A sub-analysis of the ROCKET-AF trial showed that patients with atrial fibrillation who took the new anticoagulant rivaroxaban to prevent stroke were 40% less likely to have intracranial hemorrhages than warfarin users. Researchers also found that adding clopidogrel to either warfarin or rivaroxaban increased the risk of intracranial bleeding by 250% compared with clopidogrel or warfarin alone.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA